09:25:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-02-18 Bokslutskommuniké 2024
2024-10-30 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-24 X-dag ordinarie utdelning SYNACT 0.00 SEK
2024-05-23 Årsstämma 2024
2024-04-24 Extra Bolagsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-05-26 X-dag ordinarie utdelning SYNACT 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2023-01-12 Extra Bolagsstämma 2022
2022-11-04 Kvartalsrapport 2022-Q3
2022-08-05 Kvartalsrapport 2022-Q2
2022-05-30 Kvartalsrapport 2022-Q1
2022-05-23 X-dag ordinarie utdelning SYNACT 0.00 SEK
2022-05-20 Årsstämma 2022
2022-02-11 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-24 X-dag ordinarie utdelning SYNACT 0.00 SEK
2021-05-21 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-12 Bokslutskommuniké 2020
2020-11-13 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-05-14 X-dag ordinarie utdelning SYNACT 0.00 SEK
2020-05-13 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-11 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-11-08 Extra Bolagsstämma 2019
2019-08-30 Kvartalsrapport 2019-Q2
2019-05-13 X-dag ordinarie utdelning SYNACT 0.00 SEK
2019-05-10 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-12 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-05-16 X-dag ordinarie utdelning SYNACT 0.00 SEK
2018-05-15 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-13 Bokslutskommuniké 2017
2017-11-03 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-12 X-dag ordinarie utdelning SYNACT 0.00 SEK
2017-05-11 Kvartalsrapport 2017-Q1
2017-05-11 Årsstämma 2017
2017-02-09 Bokslutskommuniké 2016
2016-11-04 Kvartalsrapport 2016-Q3


ListaSmall Cap Stockholm
SynAct Pharma är en läkemedelskoncern som bedriver forskning och utveckling inom behandlingen av inflammatoriska sjukdomar. Bolaget har utvecklat en plattformsteknologi som riktas mot allvarliga patienttillstånd inom kroniska inflammatoriska sjukdomar, samt diverse ledskador. Störst verksamhet återfinns inom den nordiska marknaden. Huvudkontoret ligger i Lund.
2023-04-03 07:00:00

SynAct Pharma AB (publ) (“SynAct”) today announced the appointment of the company’s current Chairman Torbjørn Bjerke MD, as its new Chief Executive Officer (CEO), effective as from the Annual General Meeting to be held on May 25, 2023. Dr. Bjerke succeeds Jeppe Øvlesen, who will remain a committed shareholder of the company. The Nomination Committee will propose to the Annual General Meeting that the current board member Uli Hacksell should be appointed as new Chairman of the Board.

“We are happy to welcome Torbjørn as our new CEO of SynAct. SynAct Pharma is in a transformational phase with next important clinical data in second half of this year. Having been the company’s Chairman since 2016, Torbjørn has excellent first-hand knowledge of SynAct. Also, he has great knowledge in developing successful new medicines, a fantastic global network of investors and pharma companies and extensive proven track record in business development and deal making,” said Uli Hacksell, proposed new Chairman of the Board. “We want to express our gratitude and appreciation to Jeppe for his leadership of SynAct since 2015 and being instrumental in a number of pivotal events, including the listings at Spotlight and subsequently Nasdaq Stockholm. Under Jeppe´s leadership Synact Pharma has gone from being a private company to become a valuable public company with more than 14,000 shareholders. The board accepts that he now wants to hand over the responsibility to Torbjørn who can take SynAct Pharma to the next level.”

Jeppe Øvlesen, retiring CEO of SynAct, said: “The last nine years have been an incredible journey as an entrepreneur, and I could not be prouder to hand over the baton to Torbjørn. I have been working with Torbjørn for 23 years and strongly believe that his strategic leadership and deep knowledge in biotech and securing high value partnerships make him the right next CEO to deliver tremendous value to all stakeholders, including both patients and shareholders. I will remain a committed, long-term shareholder.”

Dr. Torbjørn Bjerke commented: “Having been part of the SynAct family now for seven years, I am deeply impressed with what the company has developed in a short period of time under the leadership of Jeppe. To have a platform of molecules with the lead AP1189 that can potentially transform the way we treat inflammatory diseases like rheumatoid arthritis is very unique. It will be exciting to work with the management team and board in my new capacity and lead the company to further success. We have much to do preparing our potential partners and shareholders for the next clinical results in EXPAND and RESOLVE in parallel to developing our extensive preclinical pipeline. In addition, we need to increase the knowledge about SynAct Pharma both in Sweden and in the global arena”

Dr. Bjerke will leave his current position as Partner and portfolio manager at Arctic Asset Management. He will continue as Chairman of the advisory board of Arctic Aurora LifeScience and Biotech Select, member of the board of Biothea and Chairman of the board of Carelight Ltd. He previously served as the president and CEO of Karolinska Development AB from 2011 to 2014. Prior to that, Dr Bjerke was the president and CEO of Orexo AB, a position he held from 2007 until January 2011. Previously, he was president and CEO of Biolipox AB, Executive Vice President, R&D, ALK Abello, and director of pharmacology at AstraZeneca. Dr. Bjerke holds a MD in medicine from Aarhus Universitet, Denmark.

Dr. Bjerke is cofounder of Action Pharma AS and TXP Pharma GmbH.